Samuel R Saks - Net Worth and Insider Trading
Samuel R Saks Net Worth
The estimated net worth of Samuel R Saks is at least $0 dollars as of 2024-04-19. Samuel R Saks is the Director of Tonix Pharmaceuticals Holding Corp and owns about 0 shares of Tonix Pharmaceuticals Holding Corp (TNXP) stock worth over $0. Details can be seen in Samuel R Saks's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Samuel R Saks has not made any transactions after 2016-06-21 and currently still holds the listed stock(s).
Transaction Summary of Samuel R Saks
Samuel R Saks Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Samuel R Saks owns 4 companies in total, including Protagonist Therapeutics Inc () , PDL BioPharma Inc () , and Tonix Pharmaceuticals Holding Corp () among others .
Click here to see the complete history of Samuel R Saks’s form 4 insider trades.
Insider Ownership Summary of Samuel R Saks
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| Protagonist Therapeutics Inc | 2018-05-21 | Chief Development Officer | |
| PDL BioPharma Inc | 2019-06-20 | director | |
| Tonix Pharmaceuticals Holding Corp | 2016-06-21 | director | |
| Jazz Pharmaceuticals PLC | 2007-05-31 | director & Chief Executive Officer |
Samuel R Saks Latest Holdings Summary
Samuel R Saks currently owns a total of 1 stock. Samuel R Saks owns 0 shares of Tonix Pharmaceuticals Holding Corp (TNXP) as of June 21, 2016, with a value of $0.
Latest Holdings of Samuel R Saks
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| TNXP | Tonix Pharmaceuticals Holding Corp | 2016-06-21 | 0 | 0.16 | 0 |
Holding Weightings of Samuel R Saks
Samuel R Saks Form 4 Trading Tracker
According to the SEC Form 4 filings, Samuel R Saks has made a total of 0 transactions in Tonix Pharmaceuticals Holding Corp (TNXP) over the past 5 years. The most-recent trade in Tonix Pharmaceuticals Holding Corp is the acquisition of 0 shares on June 21, 2016, which cost Samuel R Saks around $50,000.
Insider Trading History of Samuel R Saks
- 1
Samuel R Saks Trading Performance
GuruFocus tracks the stock performance after each of Samuel R Saks's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Samuel R Saks is -49.33%. GuruFocus also compares Samuel R Saks's trading performance to market benchmark return within the same time period. The performance of stocks bought by Samuel R Saks within 3 months outperforms 0 times out of 3 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Samuel R Saks's insider trading performs compared to the benchmark.
Performance of Samuel R Saks
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | -9.43 | -49.33 | -64.13 | -78.29 | -60.2 | -75.05 |
| Relative Return to S&P 500(%) | -11.49 | -50.23 | -65.9 | -89.91 | -72.52 | -86.42 |
Samuel R Saks Ownership Network
Ownership Network List of Samuel R Saks
Ownership Network Relation of Samuel R Saks
Samuel R Saks Owned Company Details
What does Protagonist Therapeutics Inc do?
Who are the key executives at Protagonist Therapeutics Inc?
Samuel R Saks is the Chief Development Officer of Protagonist Therapeutics Inc. Other key executives at Protagonist Therapeutics Inc include director & President and CEO Patel Dinesh V Ph D , Chief Financial Officer Asif Ali , and Chief Development Officer Suneel Gupta .
Protagonist Therapeutics Inc () Insider Trades Summary
Over the past 18 months, Samuel R Saks made no insider transaction in Protagonist Therapeutics Inc (). Other recent insider transactions involving Protagonist Therapeutics Inc () include a net sale of 130,000 shares made by Patel Dinesh V Ph D , a net sale of 24,187 shares made by Asif Ali , and a net sale of 12,975 shares made by William D. Waddill .
In summary, during the past 3 months, insiders sold 92,162 shares of Protagonist Therapeutics Inc () in total and bought 0 shares, with a net sale of 92,162 shares. During the past 18 months, 174,010 shares of Protagonist Therapeutics Inc () were sold and 0 shares were bought by its insiders, resulting in a net sale of 174,010 shares.
Protagonist Therapeutics Inc ()'s detailed insider trading history can be found in Insider Trading Tracker table.
Protagonist Therapeutics Inc Insider Transactions
Samuel R Saks Mailing Address
Above is the net worth, insider trading, and ownership report for Samuel R Saks. You might contact Samuel R Saks via mailing address: 3180 Porter Drive, Palo Alto Ca 94304.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
